Department of General Surgery, Tabriz University of Medical Sciences, Imam Reza Hospital, Golgasht Street, Tabriz, Iran.
Department of Molecular Medicine Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
BMC Cancer. 2019 Jul 15;19(1):690. doi: 10.1186/s12885-019-5849-0.
Thyroid cancer is the most common endocrinology cancer that its incidence has increased in recent decades. miRNAs are new biomarkers in recent studies in the diagnosis and follow-up of these patients.
Blood and thyroid tissue samples were obtained from two groups of included patients (PTC and benign nodules), pre- and post-operation. miRNAs were extracted from these plasma samples and were measured quantitatively. After cDNA synthesis, qPCR was carried out. Then tissue samples were investigated, and their relation to miR expression was studied. These results were analyzed by paired- and independent samples t-test, and non-parametric tests.
miR-222 and miR-181a declined in PTC patients before and after surgery, significantly (P < 0.001 for both groups), with no significant difference in control group before and after surgery (P = 0.61 for miR-222 and P = 0.06 for miR-181a). The difference between the two groups, pre-and post-operation, was statistically significant (P = 0.01 for miR-222 and P < 0.001 for miR-181a). Comparing case and control groups, pre- and post-operatively, yielded no significant difference, in miR-155-5p levels (P = 0.61 and P = 0.53, respectively). Comparing PTC and control groups before surgery showed a significant difference (P = 0.01), while no significant difference was observed comparing them after surgery, in miR146-a (P = 0.27). Our results depicted a higher miR-155-5p and miR-146a expression before surgery than after it (P < 0.001 in both groups, for both miRs). We found a significant relationship between miR-222 and BRAFV600E mutation and significantly higher levels of miR-181a with increasing tumor size in PTC patients.
miR-222 showed overexpression in all PTC cases, which is indicative of a relation between miRNA and PTC. Also, comparing miR-181 and miR-146a showed a significant difference between cancerous and benign cases. miR-155-5p as an inflammatory factor, showed no significant changes, comparing two groups.
甲状腺癌是内分泌系统最常见的癌症，近年来其发病率有所增加。miRNA 是最近在这些患者的诊断和随访研究中发现的新的生物标志物。
从两组纳入的患者（PTC 和良性结节）的术前和术后获得血液和甲状腺组织样本。从这些血浆样本中提取 miRNA，并进行定量测量。合成 cDNA 后，进行 qPCR。然后对组织样本进行研究，并研究它们与 miR 表达的关系。通过配对和独立样本 t 检验以及非参数检验分析这些结果。
miR-222 和 miR-181a 在 PTC 患者手术前后均下降，差异有统计学意义（两组均 P<0.001），而对照组手术前后无显著差异（miR-222 组 P=0.61，miR-181a 组 P=0.06）。两组手术前后的差异有统计学意义（miR-222 组 P=0.01，miR-181a 组 P<0.001）。比较病例组和对照组手术前后的 miR-155-5p 水平，差异无统计学意义（分别为 P=0.61 和 P=0.53）。比较 PTC 组和对照组手术前的 miR146-a 水平，差异有统计学意义（P=0.01），而手术后比较，差异无统计学意义（P=0.27）。我们的结果显示，miR-155-5p 和 miR-146a 在术前的表达高于术后（两组均 P<0.001）。我们发现 miR-222 与 BRAFV600E 突变之间存在显著关系，并且 PTC 患者肿瘤大小增加与 miR-181a 水平显著升高之间存在显著关系。
miR-222 在所有 PTC 病例中均呈过表达，表明 miRNA 与 PTC 之间存在关系。此外，miR-181 和 miR-146a 的比较显示，癌性和良性病例之间存在显著差异。miR-155-5p 作为一种炎症因子，两组之间无显著变化。
